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Although replication-defective human adenovirus type 5 (Ad5) vectors that express
in situ the capsid-encoding region of foot-and-mouth disease virus (FMDV) have been
proven to be effective as vaccines in relevant species for several viral strains, the
same result was not consistently achieved for the O1/Campos/Brazil/58 strain. In the
present study, an optimization of the Ad5 system was explored and was proven to
enhance the expression of FMDV capsid proteins and their association into virus-like
particles (VLPs). Particularly, we engineered a novel Ad5 vector (Ad5[PVP2]OP) which
harbors the foreign transcription unit in a leftward orientation relative to the Ad5 genome,
and drives the expression of the FMDV sequences from an optimized cytomegalovirus
(CMV) enhancer-promoter as well. The Ad5[PVP2]OP vaccine candidate also contains
the amino acid substitutions S93F/Y98F in the VP2 protein coding sequence, predicted
to stabilize FMD virus particles. Cells infected with the optimized vector showed
an ∼14-fold increase in protein expression as compared to cells infected with an
unmodified Ad5 vector tested in previous works. Furthermore, amino acid substitutions
in VP2 protein allowed the assembly of FMDV O1/Campos/Brazil/58 VLPs. Evaluation
of several serological parameters in inoculated mice with the optimized Ad5[PVP2]OP
candidate revealed an enhanced vaccine performance, characterized by significant
higher titers of neutralizing antibodies, as compared to our previous unmodified Ad5
vector. Moreover, 94% of the mice vaccinated with the Ad5[PVP2]OP candidate were
protected from homologous challenge. These results indicate that both the optimized
protein expression and the stabilization of the in situ generated VLPs improved the
performance of Ad5-vectored vaccines against the FMDV O1/Campos/Brazil/58 strain
and open optimistic expectations to be tested in target animals.
Keywords: foot-and-mouth disease virus, replication-defective human adenovirus type 5, genetic vaccine,
mutated VP2 capsid protein, virus-like particles O1/Campos, neutralizing antibodies
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INTRODUCTION
Included in the A list of infectious diseases of animals of
the Office International des Épizooties (OIE), foot-and-mouth
disease (FMD) is one of the most contagious animal illnesses
that affects several species of wild and domestic cloven-hoofed
ruminants (Knight-Jones et al., 2016, 2017). Although the disease
has been circulating for a long time, it remains of major
concern to livestock farmers and official health authorities since
it causes a huge socioeconomic impact, particularly in the
agricultural sector. Due to the financial losses incurred, FMD
is still considered the major disease concerning production and
international trade in foodstuffs of animal origin, food safety,
and economic development, affecting both small- and large-scale
production (Knight-Jones and Rushton, 2013).
The causative agent, FMD virus (FMDV), is a positive-sense
single-stranded RNA virus that belongs to the genus Aphthovirus
of the Picornaviridae family. The World Reference Laboratory for
FMD lists seven FMDV serotypes [Euroasiatic serotypes O, A,
Asia1, and C and South African territories (SAT) serotypes SAT1,
SAT2, and SAT3] in seven regional endemic pools, among which
no cross-serotype protection is expected (FAO, 2020). Within the
seven serotypes described, serotype O is the most prevalent and
is distributed across six out of the seven described endemic pools
(Brito et al., 2017). Furthermore, serotype O was responsible for
the recent FMD outbreaks in Colombia (2017–2018), Ecuador
(2011), and Venezuela (2013) (Centro Panamericano de Fiebre
Aftosa, OPS, and OMS., 2019).
In FMD endemic regions, disease control is mainly achieved
by regular vaccination (Knight-Jones and Rushton, 2013; Naranjo
and Cosivi, 2013). In this regard, the currently employed vaccines
are reliant on the use of highly purified, highly concentrated,
inactivated FMDV antigen (Grubman and Baxt, 2004). Despite
their effectiveness, these vaccine formulations have several
drawbacks, including the difficulty to differentiate infected from
vaccinated animals, the need for expensive high-containment
Biosafety Level 4-OIE (BSL4-OIE) manufacturing facilities, and
the generation of large amounts of infectious virus required
for vaccine production. Another problem associated with the
traditional FMD vaccine is the risk of live virus release during the
manufacturing process or the unintentional use of incompletely
inactivated products. These disadvantages highlight the need for
new-generation genetically engineered vaccines.
At the moment, the most successful strategy in the
development of new FMDV vaccines has been the production
of a replication-defective human serotype 5 adenovirus (Ad5)
that delivers the capsid coding region of FMDV along with
the viral protease 3C (3Cpro), required for its processing
(P12A3C cassette). Initial studies reported by Mayr et al.
(1999) have shown that an Ad5 vector that delivers the capsid
and 3Cpro coding regions of FMDV A12/119/Kent/UK/32
(Ad5-A12) was effective at protecting swine from clinical
disease after direct contact challenge. Subsequently, it was
demonstrated that one dose of Ad5-A24, which contains the
P12A3C cassette from FMDV A24/Cruzeiro/BRA/55, confers
early protection against homologous FMDV challenge in swine
(Moraes et al., 2002) and cattle (Pacheco et al., 2005; Schutta
et al., 2016). More recently, it has been shown that an Ad5
expressing FMDV O/Manisa/TUR/69 antigen (Ad5-O1Man)
could fully protect swine at 7 days post-inoculation (dpi)
(Fernández-Sainz et al., 2017). Furthermore, the Adt-O1Manisa
vector in combination with Ad5-boIFNλ3, which drives the
expression of bovine IFN-λ3, completely protects cattle against
homologous challenge as early as 3 dpi (Diaz-San Segundo et al.,
2016). On the contrary, in initial efficacy studies, the Ad5-
O1/Campos/Brazil/58 (Ad5-O1C)-vectored vaccine has shown
limited performance in target species such as swine (Caron et al.,
2005). Consequently, several strategies have been implemented
to improve Ad5-O1C vaccine performance. In this regard,
the incorporation of the full-length coding sequence of the
non-structural protein 2B (Ad5.O1C.2B) enhanced the FMDV-
specific neutralizing antibody response in swine (Pena et al.,
2008) and specific vaccine-induced T cell response in cattle
(Moraes et al., 2011). On the other hand, the insertion of the
RGD motif (Arg–Gly–Asp) into the adenovirus fiber protein
(Adt.O1C.2B.RGD) did not significantly enhance vaccine efficacy
in cattle (Medina et al., 2015). However, a similar adenovirus-
vectored O1/Campos/Brazil/58 vaccine [Adt.O1C.2B.F(RGD)],
but in combination with ENABL R© adjuvant, afforded complete
protection of cattle against clinical FMD (Barrera et al., 2018).
Given that naturally occurring empty capsids in infected cells
are less abundant for most strains of serotype O than for
serotype A (Rweyemamu et al., 1979), the lack of assembled
empty capsid proteins might explain why adenovirus-vectored
subunit vaccines for the O1/Campos/Brazil/58 strain are not
as effective as the equivalents from serotype A or even
other O subtypes.
Foot-and-mouth disease virus empty capsids are safe and
as immunogenic as the intact viral particles (Rweyemamu
et al., 1979). In fact, empty capsid particles are much more
immunogenic than the individual capsid proteins or even
partially assembled sub-viral particles (e.g., pentamers) or
disrupted products (Rweyemamu et al., 1979; Doel and
Chong, 1982). FMDV empty capsids comprise identical
pentameric protein subunits held together by tenuous
non-covalent interactions, which are unstable in mildly
acidic pH conditions (Curry et al., 1995) or at elevated
temperatures (Curry et al., 1997). In this respect, attempts
to increase capsid acid or thermal stability by replacement
of some residues by others that could strengthen inter-
pentamer interactions have demonstrated to be an effective
tool for the development of improved engineered vaccines
against FMDV (Porta et al., 2013; Kotecha et al., 2015;
Scott et al., 2017).
In the present study, we generated an optimized Ad5-vectored
FMDV subunit vaccine against the O1/Campos/Brazil/58 strain
by favoring the expression of FMDV capsid proteins and their
self-association into virus-like particles. We analyzed several
serological parameters after intramuscular inoculation with
the optimized Ad5[PVP2]OP candidate in a two-dose regimen
formulated without adjuvants. Our results showed an enhanced
vaccine performance, as demonstrated by the higher total and
neutralizing antibody responses and an improved protection
upon homologous challenge in a mouse model.
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MATERIALS AND METHODS
Cells and Viruses
Human embryonic kidney 293A (HEK 293A), Madin–Darby
bovine kidney (MDBK), and baby hamster kidney 21 (BHK-
21) cell lines were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 100 U/ml of penicillin G, and 100 µg/ml of streptomycin
(Thermo Fisher Scientific). The recombinant Ad5 viruses used
in this study included: Ad5[G], which expresses the enhanced
green fluorescent protein (GFP) reporter gene (Romanutti et al.,
2013); Ad5[P], which contains the P12A polyprotein capsid
precursor and the 3Cpro coding regions (P12A3C) of the
FMDV O1/Campos/Brazil/58 strain under the control of the
cytomegalovirus enhancer-promoter (pCMV) (D’Antuono et al.,
2010; Romanutti et al., 2013); and two novel Ad5 constructions
denominated Ad5[P]OP and Ad5[PVP2]OP, which are described
below. The infectious FMDV strain O1/Campos/Brazil/58 used
for challenge experiments was supplied by the Argentine FMD
Reference Laboratory, Servicio Nacional de Sanidad y Calidad
Agroalimentaria (SENASA). All experiments involving infectious
virus were performed in the BSL4-OIE facilities at the Institute of
Virology, CICVyA, INTA.
Construction of Optimized Recombinant
Adenoviruses
Non-replicating (1E1/E3) optimized (OP) Ad5 vectors
expressing O1/Campos/Brazil/58 (O1/Campos) FMDV capsid
proteins were constructed through Gateway recombination
following the manufacturer’s instructions (Gateway System,
Thermo Fisher Scientific). Firstly, the pENTR[P]OP shuttle
plasmid was generated by inserting the pCMV, the chimeric
β-globin/IgG intron, the P12A3C sequence, and the SV40
poly(A) signal from the pCI-P12A3C plasmid (Romanutti,
2012) between the attL1–attL2 recombination sites in
pENTRTM4 (Thermo Fisher Scientific). Subsequently,
amino acid substitutions were introduced into the FMDV
VP2 full-length sequence using a QuikChange site-directed
mutagenesis kit (Agilent Technologies) using pENTR[P]OP




TGCATATATGAGAAACGG-3′, and Y98Fr 5′-CCGTTTCT
CATATATGCAAACGAGTCAGTCAGG-3′). The resulting
plasmid, designated as pENTR[PVP2]OP, contains nucleotide
changes (agc>ttc and tat>ttt) at positions corresponding to
residues S93 and Y98 of the VP2 protein sequence. Finally,
the pENTR[PVP2]OP and pENTR[P]OP shuttle vectors were
recombined in vitro into the pAd/PL/V5-DESTTM to obtain
the pAd5[PVP2]OP and pAd5[P]OP genomes, respectively
(Figures 1B,C). The correct insertion of the foreign sequences
was confirmed by restriction digestion analysis and DNA
sequencing. The final plasmids (pAd5[PVP2]OP and pAd5[P]OP)
were linearized with PacI and transfected into HEK 293A
cells using Lipofectamine 2000 (Thermo Fisher Scientific).
The recombinant Ad5[PVP2]OP and Ad5[P]OP viruses were
harvested 4–10 days post-transfection when approximately
80% cytopathic effect was observed. The Ad5 vectors were
subsequently propagated and titrated into HEK 293A cells.
Titration of Ad5 stocks was performed by the plaque-forming
unit (PFU) method according to the manufacturer’s instructions
(ViraPowerTM Adenoviral Expression System, Thermo Fisher).
Vector titers were expressed as PFUs per milliliter. The average
titers of the adenoviral stocks used in the experiments were
as follows: Ad5[P], 7.5 × 109 PFU/ml; Ad5[P]OP, 5.8 × 109
PFU/ml; and Ad5[PVP2]OP, 5.2× 109 PFU/ml.
In vitro FMDV Protein Expression
Analysis
HEK 293A cells were infected with recombinant adenoviral
particles at a multiplicity of infection (MOI) of 1. After 48 h
incubation, the cells were washed with phosphate-buffered
saline (PBS), lysed with 1× Laemmli buffer, and separated on
12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE). The fractionated proteins were transferred to
nitrocellulose membranes and probed with the corresponding
primary antibodies. Anti-FMDV O1/Campos polyclonal guinea
pig serum (Seki et al., 2009) was used as the primary antibody
to detect the production of recombinant capsid proteins. Anti-
β-tubulin monoclonal antibody (mAb; AC-15, Sigma-Aldrich)
was used as an internal control. Horseradish peroxidase (HRP)-
conjugated anti-guinea pig or anti-mouse IgG were used as
secondary antibodies (Cappel Laboratories Inc.). The blots were
developed by using SupersignaL R© West Pico Chemiluminescent
Substrate (Pierce), according to the manufacturer’s instructions.
Protein band intensity was quantified by densitometry using
ImageJ software (Abramoff et al., 2004).
Purification of FMDV Subunits by
Sucrose Gradients
HEK 293A and MDBK cells infected with Ad5 vectors at
MOI 50 or 500, respectively, were lysed in NTE isotonic
buffer (100 mM NaCl, 10 mM Tris–HCl, 1 mM EDTA, pH
7.4) containing 0.1% (v/v) Triton X-100 (Sigma-Aldrich). After
10 min incubation, the nuclei were removed by centrifugation
and the supernatants were loaded onto 10–45% sucrose gradients
in NTE and centrifuged at 22,000 rpm for 6 h in an SW28
rotor at 4◦C. Density gradient fractions were collected and
tested by enzyme-linked immunosorbent assay (ELISA) using
non-cross-reactive anti-FMDV serotype O mAbs, as previously
described (Seki et al., 2009). A stock of A/Argentina/2001
(A/Arg/01) inactivated FMD virus was also analyzed following
the same protocol, but using an anti-A/Arg/01 polyclonal rabbit
antiserum and specific mAbs against serotype A (Seki et al.,
2009). Inactivated A/Arg/01 FMDV preparation was used as
a marker of intact virions (146S), empty particles devoid of
RNA (75S), and capsomer (12S) position in the gradient given
the fact that the A/Arg/01 FMDV strain is able to generate a
detectable amount of empty particles in cell cultures (Rowlands
et al., 1975; Rweyemamu et al., 1979; Curry et al., 1995). For
the detection of FMDV capsid proteins, eight fractions from
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FIGURE 1 | Schematic structure of the recombinant adenoviral genomes. (A) Recombinant pAd5[P] carrying the foot-and-mouth disease virus (FMDV) P12A3C
cassette from O1/Campos strain (brown box) under the control of the cytomegalovirus enhancer-promoter (pCMV) in an E1/E3-deleted Ad5 backbone
(Ad51E1–E3). pA, SV40 poly(A) signal; ITR, inverted terminal repeats. (B) Recombinant pAd5[PVP2]OP. This Ad5 genome contains the expression unit at the E1
insertion site in a leftward orientation (3′→5′) in the 1E1–E3 Ad5 backbone. The expression unit contains the FMDV P12A3C cassette under the control of the
optimized pCMV (pCMV and human β-globin/IgG chimeric intron, zigzag line). Additionally, it harbors two non-synonymous substitutions in the VP2 coding sequence
to express a S93F/Y98F VP2 mutant protein. (C) Recombinant pAd5[P]OP is identical to pAd5[PVP2]OP, but expresses a native VP2 capsid protein.
the Ad5[PVP2]OP gradient were selected and concentrated by
trichloroacetic acid (TCA) precipitation (Link and Labaer, 2011).
The resultant pellets were resuspended in 1× Laemmli buffer,
applied to standard 12% SDS-PAGE gels, and then transferred
onto nitrocellulose membranes. The membranes were probed
with an anti-FMDV O1/Campos polyclonal guinea pig serum
(Seki et al., 2009) followed by the corresponding HRP-conjugated
secondary antibody.
For negative-staining transmission electron microscopy
(TEM), fractions containing FMDV subunits were adsorbed to
carbon-coated Parlodion films and mounted on 300-mesh/in.
copper grids (EMS, Fort Washington, PA, United States) for
10 min, washed once with water, and stained for 1 min with 2%
phosphotungstic acid, pH 7.0 (Sigma-Aldrich). The specimens
were analyzed in a transmission electron microscope (Zeiss
EM 109T) equipped with a CCD camera (Ultrascan ES1000W,
Gatan, Pleasanton, CA, United States) at an acceleration
voltage of 100 kV.
Quantitative Analysis of FMDV Transcript
Accumulation in vitro and in vivo
To examine the quantity of FMDV messenger RNAs (mRNAs)
accumulated in vitro, HEK 293A cells were infected with Ad5-
FMD vectors at a MOI of 5 in 12-well plates. Twenty-four hours
post-infection (hpi), the cells were harvested in TRIzol (Thermo
Fisher Scientific).
RNA was isolated following the manufacturer’s instructions
and quantified using a NanoDrop spectrophotometer. Aliquots
of 200 ng of purified total RNA were treated with RQ1
DNase, RNase-free (Promega) and then reverse-transcribed with
SuperScript II reverse transcriptase (Thermo Fisher Scientific)
using specific primers for the 3Cpro coding sequence (3Crt
5′-CTCGTGGTGTGGTTCG-3′) and human actin (Act_r, 5′-
CGTCACCGGAGTCCATCACGA-3′) housekeeping gene. The
primers for the amplification of the 3Cpro or actin 110-bp
DNA fragment were designed by Primer Express R© software
v3.0.1 (Applied Biosystems). Quantitative reverse transcription
polymerase chain reactions (RT-qPCRs) were run in triplicate
using 1/10th of the diluted complementary DNA (cDNA),
300 nmol of each primer (3Cf 5′-AAGATGGTCATGGGCA
ACAC-3′ and 3Cr 5′-CGAGGTAAGCAGTGCCAAAC-3′ or
Act_f 5′-GAGACCTTCAACACCCCAGCC-3′ and Act_r), and
10 µl of 2× FastStart Universal SYBR Green Master (Rox; Roche)
in a final volume of 20 µl. PCR cycle conditions were set as
follows: pre-incubation for 10 min at 95◦C followed by 40 cycles,
each including 15 s at 95◦C and 60 s at 60◦C. Dissociation curves
were generated at the end of the run to verify the specificity
of the reaction product. Relative quantification was performed
by Applied Biosystems 7500 Real-Time PCR software v2.0.6
(Thermo Fisher Scientific) based on “cycle threshold” (Ct) values.
Average 3Cpro Ct values were normalized to the average Ct values
for actin, and the relative level of 3Cpro (R) was estimated as
11Ct-based fold change using the 2−11Ct equation.
For transcript accumulation in vivo analysis, BALB/cJ
mice were inoculated by the intramuscular (i.m.) route with
5 × 108 PFU of either the prior Ad5[P] or the optimized
Ad5[PVP2]OP viruses (three animals per group). For transgene
transcript accumulation analysis by RT-qPCR, draining popliteal
lymph nodes (dPLNs) were isolated at 2 and 8 dpi, and
cell suspensions were obtained in TRIzol (Thermo Fisher
Scientific). cDNA synthesis was performed as described
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above, but using specific primers for 3Cpro (3Crt) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDHqr,
5′-CAGAAGGTGCGGAGATGATGA-3′) included as the
housekeeping gene. RT-qPCR reactions were also run in triplicate
using 1/10th of the diluted cDNA, 300 nmol of each primer (3Cf
and 3Cr or GAPDHqf 5′-TGCTGGTGCCGAGTATGTTG-3′
and GAPDHqr). Average 3Cpro Ct values were normalized to
the average Ct values for GAPDH, and the relative level of
3Cpro (R) was estimated as 11Ct-based fold change using the
2−11Ct equation.
Experimental Animals and Immunization
Protocols
In the present study, a murine model was employed as a
predictor of the immunogenicity and protection induced by
Ad5-based FMD vaccines (Bidart et al., 2020; Gnazzo et al.,
2020). The experiments carried out in mice reported in
this manuscript have been performed following internationally
recognized guidelines with the approval of the Institutional
Committee for Care and Use of Experimental Animals, CICUAE
(approval reference CICUAE CEVAN 01.1/2020, 02.1/2020, and
INTA-CICVyA 10/2020).
Groups of 16 mice (4- to 6-week-old male BALB/cJ mice)
were injected i.m. with 50 µl of the Ad5[PVP2]OP vaccine
candidate (5 × 108 PFU per animal). For comparison purposes,
three additional groups of mice were inoculated with Ad5[P]OP
(n = 16), Ad5[P] (n = 8), or a commercial oil-adjuvanted
inactivated O1/Campos strain vaccine (IV; n = 12). Animals
inoculated with a recombinant Ad5 expressing GFP (Ad5[G]),
considered as an unrelated antigen, were also included (n = 8).
According to the 3R’s (replacement, reduction, and refinement),
and due to ethical limitations, the number of animals used in each
experimental group was reduced when possible, as in the case of
groups inoculated with Ad5[P], Ad5[G], and IV. These groups
were included only as control groups since they were already
evaluated in previous works (D’Antuono et al., 2010; Romanutti
et al., 2013). Table 1 summarizes the treatments given to the
different groups of mice. Individual serum samples were collected




Anti-FMDV antibody titers were estimated by ELISA, following
a modified protocol from Seki et al. (2009). Briefly, ELISA
microplates (MaxiSorpTM, Nunc) were coated with a rabbit
antiserum against the FMDV O1/Campos strain in carbonate–
bicarbonate buffer (pH 9.6) and incubated overnight (ON) at
4◦C. The inactivated O1/Campos 146S particles were then added
to the wells and incubated for 1 h at 37◦C. Subsequent steps
were performed using a blocking buffer (PBS containing 3%
horse serum and 0.05% Tween-20). Murine sera to be tested
were serially diluted in blocking buffer and subsequently added
to the coated ELISA plate and incubated for 1 h at 37◦C.
Peroxidase-labeled anti-mouse IgG, IgG1, or IgG2a antibodies
were used to develop the reactions. Antibody (Ab) titers were
expressed as the log10 of the reciprocal of serum dilutions giving
at least twice the absorbance at 405 nm estimated in sera from
animals inoculated with Ad5[G], which represents the negative
control condition. Isotyping of the Ab response was carried out
in sera at 45 dpi.
To examine the antigen avidity index, the plates were coated
ON at 4◦C with purified O1/Campos FMDV 146S particles
in 50 mM carbonate/bicarbonate buffer (pH 9.6). After five
washes with PBS-T (PBS with 0.05% Tween-20), 50 µl of
a single dilution of serum samples (1/50) was added and
incubated for 1 h at 37◦C. The plates were washed twice with
PBS-T and subsequently incubated with PBS–4 M urea for
15 min at room temperature, followed by two PBS-T washing
steps. FMDV-specific antibodies were detected with the HRP-
labeled anti-mouse conjugate incubated for 1 h at 37◦C. The
colorimetric reaction was revealed with the chromogen/substrate
mixture ABTS/H2O2 at room temperature. The reaction was
stopped after 30 min by the addition of 2% sodium fluoride
and the absorbance was read at 405 nm. The optical density
(OD) values of the samples were corrected by subtracting the
mean blank OD values (cOD). The avidity index (AI) was
calculated as the percentage of residual activity of each serum
relative to the cOD of the untreated (not washed with urea)
sample: AI% = (cOD sample with urea/cOD sample without
urea) × 100 (Lavoria et al., 2012; Romanutti et al., 2013;
Bidart et al., 2020).
TABLE 1 | Mice immunization schedule.
Immunogensa
Prime (day 0) Boost (day 28) Adjuvant Dose (PFU) Inoculation route Challengeb (day 49)
Ad5[P]OP Ad5[P]OP – 5 × 108 i.m. Yes
Ad5[PVP2]OP Ad5[PVP2]OP – 5 × 108 i.m. Yes
Ad5[P] Ad5[P] – 5 × 108 i.m. Yes
Ad5[G] Ad5[G] – 5 × 108 i.m. Yes
PBS IV + 1 µg i.p. Yes
IV, oil-adjuvanted inactivated commercial O1/Campos strain vaccine (Aftogen; BiogenesisBago, Argentina); P, P12A3C sequence from FMDV O1/Campos; G, green
fluorescent protein; PFU, plaque-forming units.
aDetail of the immunogens used in each experimental group.
b104.5 TCID50 of FMD infective virus.
Frontiers in Microbiology | www.frontiersin.org 5 November 2020 | Volume 11 | Article 591019
fmicb-11-591019 October 29, 2020 Time: 17:38 # 6
Ziraldo et al. Optimized Adenovirus-Vectored FMDV Vaccine
Virus Neutralization Test
Sera were examined for anti-FMDV O1/Campos neutralizing
antibodies (nAbs) as described before (Quattrocchi et al.,
2014). Briefly, serial dilutions of complement inactivated sera
were incubated for 1 h at 37◦C with 100 fifty percent
tissue culture infective dose (TCID50) of the infective FMDV
O1/Campos. Then, virus–serum mixtures were seeded on BHK-
21 monolayers. After 40 min at 37◦C, fresh DMEM 2% fetal calf
serum (FCS) was added to the monolayers, which were incubated
at 37◦C under 5% CO2. Cytopathic effects were observed after
48 h. Titers are expressed as log10 of the reciprocal of the serum
dilution that neutralizes 50% of 100 TCID50 of the infective
FMDV O1/Campos using the fixed virus–variable serum method.
Virus Challenge
Mice were challenged by intraperitoneal (i.p.) inoculation of 104.5
TCID50/ml of infective FMDV O1/Campos strain per mouse. The
groups of mice described in Table 1 were challenged at 49 dpi
in BSL4-OIE facilities and analyzed for the presence of viremia
24 h post-challenge. Protection against FMDV was assessed as
previously described, with minor modifications (Carrillo et al.,
1998; Quattrocchi et al., 2011). Twenty-four hours after challenge
(50 dpi), the animals were anesthetized and bled by the retro-
orbital route. Heparinized blood was spread undiluted on BHK-
21 cell monolayers; after virus adsorption, the monolayers were
washed with sterile PBS. Fresh DMEM with 2% FCS was added
and the cells were kept for 48 h at 37◦C in a 5% CO2 incubator.
An animal was considered protected if the cell monolayer did
not present a cytopathic effect after a blind passage. Protection
percentages were calculated as P% = (number of protected
mice/number of challenged mice)× 100.
Bone Marrow Dendritic Cells Isolation
Bone marrow was obtained from the femurs and tibias of 8-week-
old C57BL/6J males by flushing RPMI 1640 medium through the
bone interior. Then, red blood cells were lysed and the cells were
cultured at 37◦C and 5% CO2 in six-well plates (1.5 × 106 cells
per well) in 2 ml of RPMI 1640 containing 10% FBS, 50 µg/ml
gentamycin (Sigma), and 20 ng/ml of recombinant GM-CSF
(GenScript). The media was renovated on days 3 and 5, and on
day 8 the cells were harvested and the percentage of bone marrow
dendritic cells (BMDCs) was determined by the co-expression
of CD11c and major histocompatibility complex (MHC) class II
surface markers.
BMDCs Activation
Bone marrow dendritic cells (5 × 105 cells/well) were stimulated
with 500 ng/ml lipopolysaccharide (LPS) as a positive control
condition or infected with Ad5[P] or Ad5[PVP2]OP at different
MOIs (50 and 250) for 1 h at 37◦C and 5% CO2 in RPMI 1640.
Then, the supernatant was removed and RPMI 1640 containing
10% FBS was added and the cells were incubated at 37◦C and 5%
CO2. After 24 h, the cells were washed and resuspended in 100 µl
of ice-cold PBS–azide plus anti-FcγR mAb (CD16/32; clone 93)
and incubated for 30 min on ice. Then, APC anti-mouse CD11c
(clone M1/70), FITC anti-mouse MHC-II (clone M5/114.15.2),
PE anti-mouse CD80 (clone 16-10AI), and PerCP anti-mouse
CD86 (clone PO3) mAbs were added in the recommended
concentrations and incubated for additional 40 min on ice. Next,
the cells were washed, fixed with 1% p-formaldehyde in PBS, and
analyzed by flow cytometry. FlowMax cytometer PASIII (Partec,
Münster, Germany) and Flowjo software (FlowJo, Ashland, OR,
United States) were used for the analysis. All mAbs and their
isotype controls were from Biolegend.
Sequence Analysis and Prediction of
FMDV VP2 Structure
All sequences were retrieved by BLAST using FMDV O1/Campos
VP2 (Uniprot accession no. Q8UZC1) as the query in the NCBI
non-redundant database. Multiple sequence alignments were
done by t_coffee (Di Tommaso et al., 2011) on a set of 116 non-
redundant VP2 sequences and on a subset of 22 representative
VP2 sequences. Amino acid conservation scores were retrieved
from The ConSurf Server1(Berezin et al., 2004; Ashkenazy
et al., 2016). Both alignments exhibited comparable conservation
scores at the analyzed positions. Data are available upon request.
A three-dimensional (3D) model of the O1/Campos VP2 protein
was created with MODELLER (Marti-Renom et al., 2000; Eswar
et al., 2006) based on the full-length FMDV O1 crystal structure
[Protein Data Bank (PDB) code 1QQP.3] (Fry et al., 1993).
Validation of the model was carried out by ProSA (Wiederstein
and Sippl, 2007) and Verify3d (Eisenberg et al., 1997). Also,
the stereochemical quality of the model was assessed by the
Ramachandran plot using PROCHECK (Laskowski et al., 1993).
Superimposition (Maiti et al., 2004) with 1QQP.3 gave a global
root mean square deviation (RMSD) of 0.32 Å across 216
equivalent positions. The interfacing region at the inter-pentamer
contact of FMDV O1/Campos VP2 was modeled using the PDB
coordinates 1BBT and 5DDJ as templates. All the evaluations
supported the correctness of the models.
Statistical Analysis
Statistical analysis was performed using the GraphPad Prism 6
software (CA, United States). Comparison between mean values
of the two groups (i.e., mean Ab titers) was assessed by unpaired
non-parametric Mann–Whitney test. Comparison of the RNA
levels in infected cells and dPLNs as well as the activation marker
levels among the different Ad5-infected BMDCs was performed
using two-way analysis of variance (ANOVA). Differences were
considered significant for p < 0.05.
RESULTS
Rational Design of Optimized
Recombinant Ad5 Viruses
Previously, we have described an adenovirus vector (Ad5[P])
that contains the FMDV O1/Campos P12A polyprotein and
3Cpro coding regions placed under the control of the pCMV
into the E1 locus in the rightward orientation (5′→3′) relative
1https://consurf.tau.ac.il/
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to the Ad5 genome (D’Antuono et al., 2010; Romanutti et al.,
2013). Ad5[P] (Figure 1A) was able to express and properly
process the FMDV capsid proteins, but it was unable to
induce protective immunity in a murine experimental model
(D’Antuono et al., 2010; Romanutti et al., 2013). Therefore,
to improve the Ad5-vectored O1/Campos subunit vaccine
performance, we explored the impact of increasing the expression
levels of FMDV capsid proteins as well as improving their
ability to self-associate into VLPs on vaccine immunogenicity
and efficacy. Accordingly, we engineered an optimized novel Ad5
vector that contains modifications in the FMDV autonomous
expression unit.
Firstly, to enhance the expression of the O1/Campos
capsid proteins, we placed the P12A3C transgene under
the transcriptional control of an optimized pCMV, which
comprises the pCMV and the human chimeric β-globin/IgG
intron regulatory element, which is well known to produce
strong intron-mediated enhancement-related effects on mRNA
expression (Buchman and Berg, 1988; Wu et al., 2008; Choi
et al., 2014). Additionally, in order to avoid aberrant splicing
between the transgene and the adenoviral genes, the FMDV
expression unit was embedded into the E1 locus in a leftward
orientation (3′→5′) (Rubinchik et al., 2001; Nakai et al., 2007;
Suzuki et al., 2015). Secondly, to favor the self-assembly of the
FMDV O1/Campos capsid proteins into VLPs, we introduced
substitutions in amino acids located in the N-terminal of the
VP2 capsid protein, whose side chains are engaged in inter-
pentamer interactions. In particular, the replacements S93F
and Y98F were described as essential to increase the pH and
thermal stability of the less stable FMD O1/Manisa and SAT2
virus particles and recombinant empty capsids (Kotecha et al.,
2015; Rincon et al., 2015; Ganji et al., 2018). We surmised
that introducing these mutations in both residues would
favor O1/Campos empty capsid formation in situ. Therefore,
we defined the presence and disposition of these relevant
residues involved in VP2–VP2 contacts at the capsid inter-
pentamer interfaces. To that end, we generated a molecular
model of the VP2 monomer employing the 3D structure of
FMDV O1BFS (99% sequence identity) as a template (PDB
1BBT). Based on the location in this model, as well as
on the conservation score of the individual positions across
seven representative FMDV O subtypes in multiple sequence
alignments (data not shown), strictly conserved amino acids
S93 and Y98 were corroborated as candidates for mutagenesis
(Figure 2). By this rationale, we generated the Ad5[PVP2]OP
vaccine candidate that contains the leftward-directed FMDV
expression unit under the control of the optimized pCMV.
Additionally, it carries two non-synonymous substitutions in
the VP2 coding sequence to express a S93F/Y98F VP2 mutant
protein (Figure 1B).
Complementary, to evaluate specifically the contribution of
the introduced double mutation upon the in vitro VLP assembly
as well as its influence on the induction of adaptive immune
response in mice, we also generated the Ad5[P]OP vector to
be used as a control. Regarding expression unit structure and
orientation, this vector is identical to Ad5[PVP2]OP, but expresses
a wild-type VP2 capsid protein (Figure 1C).
Expression of FMDV O1/Campos Capsid
Proteins in Mammalian Cells
In the first place, we evaluated the impact of the optimization
approach in FMDV capsid protein expression. To that end,
HEK 293A cells were infected with Ad5[PVP2]OP or Ad5[P]OP,
and FMDV capsid protein accumulation was analyzed by
Western blot using a polyclonal Ab against O1/Campos FMDV
(Figure 3A). As expected, neither VP0, VP3, nor VP1 was
detected upon infection with Ad5[G] (lane 1). A discrete band
corresponding to the mature capsid proteins VP0, VP1, and
VP3 was identified in lysates from Ad5[P]-, Ad5[P]OP-, and
Ad5[PVP2]OP-infected cells (lane 2, 3, and 4, respectively),
indicating that these vectors are able to deliver the expression of
FMDV polyprotein, which is properly processed. Interestingly,
cells infected with either the Ad5[PVP2]OP or Ad5[P]OP vector
also yielded a quantitative stronger signal than those cells
infected with Ad5[P], indicative of an increased capsid protein
accumulation. Quantification by ELISA (data not shown) and
densitometry (samples infected at a MOI of 1) indicated an
approximately 14-fold increase in VP0 accumulation in cells
infected with Ad5[PVP2]OP or Ad5[P]OP vectors as compared
to Ad5[P] (Figure 3A). Moreover, no remarkable differences
on the FMDV protein expression levels were observed between
the cells infected with Ad5[P]OP or Ad5[PVP2]OP (lanes 3 and
4, respectively). Consistently, HEK 293A cells infected with
the Ad5[P]OP or Ad5[PVP2]OP vectors accumulated significantly
higher levels of 3Cpro mRNA (two-fold increase) when compared
to those infected with the Ad5[P] vector (Figure 3B).
In brief, these results showed that the insertion of the
optimized leftward-directed FMDV expression unit boosts
FMDV capsid protein expression through enhanced FMDV
transcript levels delivered by the Ad5 vector. This phenomenon
does not correlate with the introduction of S93F and Y98F
substitutions within the VP2 capsid protein.
Characterization of Capsid-Like Particles
Assembled in Ad5[PVP2]OP-Infected Cells
Subsequently, the effect of the targeted amino acid mutations
on the FMDV VP2 capsid protein in the self-assembly of empty
capsids was investigated. In preliminary experiments, we found
that ultracentrifugation in sucrose gradients of lysates derived
from non-permissive MDBK cells infected with Ad5[PVP2]OP
showed a sedimentation pattern consistent with the generation
of 75S FMDV subunits (Supplementary Figure S1).
To confirm whether this finding was specific for the VP2-
introduced mutations, lysates from HEK 293A cells infected
with Ad5[PVP2]OP, Ad5[P], or Ad5[P]OP were analyzed by
sucrose gradient ultracentrifugation and the resulting fractions
were examined using serotype-specific antigen ELISAs (Seki
et al., 2009). Considering that FMDV O1/Campos does not
produce easily detectable native empty particles in cell cultures,
inactivated FMDV A/Argentina/2001 (A/Arg/01) was analyzed
in parallel as a marker for 146S, 75S, and 12S particles.
In lysates from cells infected with Ad5[P], Ad5[P]OP, or
Ad5[PVP2]OP, FMDV capsid proteins predominantly associated
in macromolecular complexes that sedimented at a lower rate
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FIGURE 2 | Rational design to produce empty capsids of foot-and-mouth disease virus (FMDV) O1/Campos. (A) Scheme of the icosahedral FMDV capsid.
A protomer consisting of VP1, VP2, VP3, and the internal polypeptide VP4 (not visible) is shown in orange. The interface between two pentamers at the two-fold
symmetry axis, where two neighboring VP2–VP2 interact, is enclosed within a dashed rectangle. (B) The VP2 structure of FMDV O1/Campos was modeled as
described in the section “Materials and Methods”. This model led to the prediction and potential localization of residues S93 and Y98, located on the α-helix A
(amino acids K88–Y98) at the two-fold symmetry axis.
than did the empty capsids (fractions 23–36) (Figure 4A).
However, in Ad5[PVP2]OP-infected cell lysates, a fraction of the
self-assembled subunits was detected at the same rate as the native
empty FMDV strain A/Arg/01 capsids (75S). The absence of the
75S fraction in the lysates from cells infected with Ad5[P]OP
is indicative that amino acid substitutions S93F and Y98F
(introduced into the VP2 sequence) favor FMDV empty capsid
particles assembly in situ. Distribution analysis of the FMDV
capsid proteins throughout the sucrose gradient from HEK
293A cells infected with Ad5[PVP2]OP by Western blot revealed
specific bands corresponding to VP0 (37 kDa) and VP1/VP3
(23 kDa) (Figure 4B). We roughly quantified the amount of
VLPs produced in cells infected with the Ad5[PVP2]OP vector by
estimating the area under the curve. According to this method,
VLPs represented approximately 12 ± 5% of the total antigenic
material produced in infected cells. These results were confirmed
by indirect ELISA using a linear standard curve derived from a
reference 146S O1/Campos FMDV (data not shown).
Finally, fractions were obtained from the middle of the
gradients (fractions 15–20) and were analyzed by negative-
staining TEM. VLPs of approximately 30 nm in diameter could
be observed in the fractions derived from HEK 293A cells
infected with the Ad5[PVP2]OP candidate (Figure 4C, right).
These structures were indistinguishable from the native empty
viral particles generated by A/Arg/01 (Figure 4C, left). Thus,
the Ad5[PVP2]OP vaccine candidate favors the production of
uniform round O1/Campos VLPs with a diameter of about
30 nm, which is similar to the average diameter of the authentic
FMDV particles.
In vivo Expression of FMDV Transgene
Our in vitro results indicated that the Ad5[PVP2]OP vaccine
candidate is more efficient in supporting FMDV capsid protein
expression than the initial Ad5[P] vector. Thereafter, we tested
whether the use of the leftward-directed FMDV expression unit
containing the optimized pCMV would enhance FMDV mRNA
accumulation in vivo. To that end, mice were inoculated with
Ad5[G], Ad5[P], or Ad5[PVP2]OP and FMDV 3Cpro transcript
accumulation was assessed at 2 and 8 dpi in mouse dPLNs
by RT-qPCR (Figure 5). At 2 dpi, animals inoculated with
the Ad5[PVP2]OP candidate accumulated approximately twofold
increased levels of 3Cpro transcripts compared with those
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FIGURE 3 | Analysis of foot-and-mouth disease virus (FMDV) capsid protein expression. Lysates of human embryonic kidney (HEK) 293A cells infected with Ad5[P],
Ad5[P]OP, or Ad5[PVP2]OP were analyzed by SDS-PAGE and Western blot using FMDV anti-O1/Campos polyclonal serum (A). An Ad5 encoding an irrelevant antigen
(green fluorescent protein), Ad5[G], was also included. To estimate FMDV structural protein accumulation, the ratios of VP0 to β-tubulin bands were calculated and
normalized to the Ad5[P] VP0/β-tubulin ratio, set at 1.0. Mean values from two independent experiments are presented. Standard deviations ranged from 0% to 2%
(not shown). VP0, VP1/VP3, and β-tubulin are indicated with an arrow. (B) Analysis of 3C mRNA expression in HEK 293A cells infected with Ad5[G], Ad5[P],
Ad5[P]OP, or Ad5[PVP2]OP by quantitative real-time PCR. HEK 293A cells were infected with the corresponding Ad5 vector at multiplicity of infection (MOI) 5.
Twenty-four hours post-infection, total RNA was isolated and used to amplify a fragment of the FMDV 3Cpro open reading frame (ORF) and, as a control, a fragment
of human Actin ORF by RT-qPCR. For each experimental group, the FMDV 3Cpro transcript level relative to the Ad5[P] group was calculated by using the 2−11Ct
equation. Data correspond to the average and standard deviation from two independent experiments. *p < 0.01 (ANOVA).
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FIGURE 4 | Assembly of recombinant capsid proteins into subviral particles. (A) Lysates of HEK 293A cells infected with Ad5[P], Ad5[P]OP, or Ad5[PVP2]OP were
loaded onto 10–45% sucrose gradients. Inactivated native A/Argentina/2001 foot-and-mouth disease virus (iFMDV A/Arg/01) was also included as a marker (black
dotted line). Fractions were collected after centrifugation at high speed and analyzed by ELISA. The positions of the FMDV virions (146S), empty capsids (75S), and
capsomers (12S) are indicated. (B) Eight fractions (5, 10, 15, 20, 25, 30, 35, and 40) were analyzed by Western blot with specific anti-FMDV O1/Campos polyclonal
antibody. VP0 and VP1/VP3 are indicated with an arrow. (C) Negative-staining TEM of in situ generated FMDV empty capsid particles (right) and iFMDV 146S and
75S particles (left). Scale bar, 50 nm. Virus-like particles are indicated (filled inverted triangle).
inoculated with the previous Ad5[P] (p < 0.01). Furthermore,
despite a decline, 3Cpro transcripts were still detected in mice
inoculated with the Ad5[PVP2]OP candidate at 8 dpi. These data
indicate that the Ad5[PVP2]OP vaccine candidate also drives the
expression of higher levels of FMDV mRNA than the Ad5[P]
vector in vivo.
Frontiers in Microbiology | www.frontiersin.org 10 November 2020 | Volume 11 | Article 591019
fmicb-11-591019 October 29, 2020 Time: 17:38 # 11
Ziraldo et al. Optimized Adenovirus-Vectored FMDV Vaccine
FIGURE 5 | Comparative detection of foot-and-mouth disease virus (FMDV)
transcripts in draining popliteal lymph nodes (dPLNs) of inoculated mice.
Comparison of transcript accumulation levels in dPLNs after inoculation of
BALB/cJ mice. Animals (n = 3) were inoculated i.m. with 5 × 108 PFU of
Ad5[G], Ad5[P], or Ad5[PVP2]OP. Total RNA was extracted from dPLNs at 2
and 8 dpi, respectively, and a fragment of the FMDV 3Cpro open reading
frame (ORF) and the GAPDH ORF were amplified by RT-qPCR. For each
experimental group, the FMDV 3Cpro transcript level relative to the Ad5[P]
group was calculated by using the 2−11Ct equation. Data correspond to the
average and standard deviation from two independent experiments. *p < 0.01
(ANOVA).
Antibody Response After Immunization
With Recombinant Ad5 Vectors
Immunogenicity experiments comparing the prior Ad5[P] vector
and the newly optimized Ad5[PVP2]OP vaccine candidate were
assessed in mice following the inoculation schedule shown in
Table 1. In order to understand the nature of the immune
response afforded by Ad5[PVP2]OP, we also analyzed the
immunogenicity of the assembly deficient Ad5[P]OP vector.
Anti-FMDV endpoint ELISA was performed with serum from
individual animals bled at −2, 21, 35, and 45 dpi. As was
previously reported (D’Antuono et al., 2010; Romanutti et al.,
2013), after the first dose (21 dpi), significant differences in
specific Ab titers could not be established between the different
experimental groups of mice (data not shown). The Ab titers
significantly increased in all groups after a booster immunization
(35 dpi), with no further increase at 45 dpi (Figure 6A). Animals
primed and boosted with the optimized vector Ad5[PVP2]OP
or Ad5[P]OP developed specific FMDV Ab titers that were
significantly higher than the ones elicited by the animals
inoculated with Ad5[P] and similar to those by the animals
primed with the oil-adjuvanted inactivated O1/Campos FMDV
vaccine (p < 0.05). As expected, the administration of a vector
encoding an unrelated antigen, Ad5[G], did not elicit measurable
anti-FMDV antibodies (not shown).
The Ab isotype analysis at 45 dpi revealed that the sera
from animals vaccinated with both optimized vectors induced
higher FMDV-specific IgG1 and IgG2a titers than Ad5[P], but
interestingly, Ad5[PVP2]OP and Ad5[P]OP evoked IgG2a as the
predominant isotype (p < 0.05; Figures 6B,C), similar to the
animals vaccinated with the oil-adjuvanted inactivated vaccine.
Therefore, Ad5[PVP2]OP and Ad5[P]OP seemed likely to induce
a Th1-dependent humoral immune response and showed the
highest IgG2a-to-IgG1 ratio of all the experimental groups.
To extend this analysis, we compared the avidity of
specific FMDV antibodies in each experimental group. Specific
antibodies elicited at 45 dpi by the inoculation of Ad5[PVP2]OP,
Ad5[P]OP, or Ad5[P] had similar high avidity indexes (>50%),
which did not differ significantly from those promoted by the
inactivated conventional FMDV vaccine (Figure 6D).
As a whole, these data indicate that the expression levels
of FMDV antigens driven by the Ad5[PVP2]OP and Ad5[P]OP
vectors were sufficient to elicit a strong immune response
comparable to the oil-adjuvanted inactivated O1/Campos FMDV
commercial vaccine.
Protection From Challenge
According to the immunization scheme shown in Table 1,
animals were challenged at 49 dpi with the infective O1/Campos
virus strain and were analyzed for the presence of viremia 24 h
post-challenge. As shown in Figure 7A, protection was found
in 62.5% (10 out of 16) of the Ad5[P]OP group and 94% (15
out of 16) of the Ad5[PVP2]OP group. No protection (0%) was
found in the groups inoculated with Ad5[P] or Ad5[G], and 100%
protection was observed in animals inoculated with one dose of
the inactivated commercial FMDV vaccine (12 out of 12).
Animals vaccinated with either the Ad5[PVP2]OP or Ad5[P]OP
vector developed specific FMDV-neutralizing Ab responses
(Figure 7B). As expected, the highest nAb titers were found in
mice inoculated with the inactivated commercial FMDV vaccine
(1.60 ± 0.15). However, the mean of the nAb titer of the group
inoculated with Ad5[P]OP remained near the test detection limit
(1.36 ± 0.02), while the mean titer of the group inoculated
with the Ad5[PVP2]OP vaccine candidate (1.45 ± 0.03) was
significantly higher than that of Ad5[P]OP (p = 0.0175) and was
consistent with the afforded protection (Figure 7A). For animals
of the non-protected groups (Ad5[P] and Ad5[G]), the nAb titers
were found to be below the assay detection limit (<1.3).
In vitro Stimulation of BMDCs With
Ad5[P] and Ad5[PVP2]OP
Dendritic cells are potent antigen-presenting cells that initiate
and modulate the host immune response. Our in vivo data
showed that Ad5[PVP2]OP is highly immunogenic and is the most
efficient in conferring protection after homologous challenge.
Since Ad5[P] and Ad5[PVP2]OP are antigenically equivalent
and only differ in their ability to deliver FMDV subunits,
we sought to determine the effect of these gene transfer
vectors on the activation phenotype of mouse BMDCs. To
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FIGURE 6 | Immune responses in mice after the administration of Ad5[P]OP and Ad5[PVP2]OP particles. (A) Kinetics of foot-and-mouth disease (FMD)
antigen-specific antibodies in BALB/cJ mice. The syringe indicates the booster inoculation (at 28 dpi). Asterisks indicate statistical significance in antibody titers
(p < 0.05). FMD virus (FMDV)-specific antibody titers were determined by enzyme-linked immunosorbent assay (ELISA) in sera from animals bled at 35 and 45 days
post-inoculation. (B) Isotype antibody profile induced by different Ad5 candidates. ELISA titers of anti-FMDV-specific IgG1 or IgG2a determined at 45 dpi are shown.
Asterisk indicates the statistically significant difference between the IgG1 and IgG2a levels (p < 0.05). (C) IgG2a/IgG1 ratio measured in each experimental group.
The consistency of the IgG ratios was assessed through the determination of the significant differences in the titers of both isotypes in each group (shown at the top
of the bars). (D) Avidity of the antibodies induced by different immunogens. Serum samples from inoculated mice at 45 dpi were used to estimate the avidity index as
a percentage. The average index corresponded to the optical density (OD) 405 nm of the urea-treated samples divided by the OD 405 nm of those PBS-treated.
Dots correspond to values from individual animals of the indicated group; the mean value is indicated (solid line).
that end, BMDCs were infected with Ad5[P] or Ad5[PVP2]OP
at different MOIs (50 or 250) or mock-infected. Twenty-
four hours later, the BMDC phenotype was assessed by using
flow cytometry analysis for CD80, CD86, and MHC-II surface
expression. As expected, treatment of mouse BMDCs with
LPS, included as a maturation control, resulted in a significant
upregulation of MHC-II, CD80, and CD86 expression (Figure 8).
Infection of mouse BMDCs with Ad5[P] or Ad5[PVP2]OP
at MOI 50 did not induce the upregulation of any of the
studied surface markers. In contrast, infection with Ad5[P] or
Ad5[PVP2]OP at MOI 250 led to a twofold increase of the
MHC-II, CD80, and CD86 expression levels as compared to
non-infected BMDCs. Overall, these results suggest that BMDC
activation depended on a threshold dose since no effect on
maturation was apparent at a MOI of 50, and the maturation
rate at a MOI of 250 was similar to that induced by LPS.
Notably, both Ad5[P] and Ad5[PVP2]OP stimulated a strong
activation of mouse BMDCs.
DISCUSSION
Although recombinant adenovirus vectors have demonstrated
promising capabilities as vaccine candidates for several
FMDV strains (Grubman et al., 2009), it has been more
difficult to achieve the same results with some strains of
serotype O, specifically for the epidemiologically relevant
O1/Campos/Brazil/58 strain (Caron et al., 2005; D’Antuono
et al., 2010; Moraes et al., 2011; Romanutti et al., 2013;
Medina et al., 2015).
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FIGURE 7 | Protection against challenge with infectious foot-and-mouth
disease virus (FMDV) O1/Campos. (A) Protection from viral challenge elicited
by the different Ad5-FMD vectors. Groups of mice were inoculated with
Ad5[P], Ad5[P]OP, Ad5[PVP2]OP, Ad5[G], or a commercial FMD vaccine and
challenged with infective FMDV at 49 dpi. Animals were considered protected
if viremia was absent after a blind passage. Protection percentages were
calculated as 100 × (number of vaccinated animals without viremia/number of
vaccinated animals). (B) Virus neutralization test (VNT) at day 45
post-inoculation with 5 × 108 PFU, expressed as log10 of the reciprocal of the
serum dilution that neutralizes 50% of 100 TCID50 of infective FMDV
O1/Campos (fixed virus–variable serum method). *p < 0.05, **p < 0.01 with
respect to the Ad5[P] group. A serum pool was made every two animals of a
group in order to perform the serum neutralization test.
It is known that the performance of FMDV vaccines is
dependent on the amount of intact viral particles (146S) (Terry
et al., 1982) or natural empty capsids (75S) (Rweyemamu et al.,
1989) in the vaccine’s preparation. In this study, we explored
the hypothesis that enhanced expression of the FMDV capsid
proteins and their self-association into VLPs would improve
the immunogenicity and efficacy of the Ad5-FMD O1/Campos
vaccine. Thereby, a novel recombinant Ad5-vectored vaccine
(Ad5[PVP2]OP) was engineered by modifying the sense of
transcription of the foreign expression unit and by expressing
the FMDV proteins from an optimized pCMV. The hypothesis
was further co-implemented with the introduction of specific
amino acid replacements (S93F and Y98F) within the N-terminal
of VP2, reported to stabilize the generated empty capsids
(Kotecha et al., 2015).
The in vitro data reported in this work support the working
hypothesis and revealed a substantial increase (∼14-fold) in
FMDV capsid protein accumulation in cells transduced with the
optimized Ad5[PVP2]OP (and also Ad5[P]OP) vector compared
with those cells transduced by our group’s first-generation
vector, Ad5[P] (Figure 3A). Moreover, the Ad5[PVP2]OP
vaccine candidate was able to deliver an increased FMDV
transcript accumulation (Figure 3B). Therefore, these results
showed that the insertion of the heterologous transcription
unit in the leftward orientation relative to the Ad5 genome,
and the expression of FMDV sequences from an optimized
pCMV, led to an increase in mRNA and capsid protein
accumulation levels in transduced cells. The data was very
relevant since Pena et al. (2008) reported a 1.5- to 1.7-fold
increase when using an identical CMV enhancer/promoter
and chimeric intron combination to drive the expression
of FMDV A24 Cruzeiro capsid proteins, indicating that the
positioning of the optimized P12A3C expression unit in an
opposite transcriptional orientation relative to the Ad5 genome
is a suitable additional strategy for optimizing FMDV gene
expression in vitro (Rubinchik et al., 2001; Nakai et al., 2007;
Suzuki et al., 2015).
As predicted, the Ad5[PVP2]OP vaccine candidate was able
to drive the assembly of FMDV O1/Campos VLPs in infected
permissive and non-permissive cells, while Ad5[P] and Ad5[P]OP
were not. Sucrose gradients of Ad5[PVP2]OP-infected cells
showed a FMDV protein fraction sedimenting at the same
rate as the native empty particles (75S) of the A/Arg/01 strain
produced in culture (Figure 4A and Supplementary Figure S1).
Indeed, examination by negative-staining TEM revealed that the
O1/Campos VLPs closely resemble the native FMD empty capsid
particles in size and overall particle morphology (Figure 4C).
Thus, the introduced double-phenylalanine substitution at
positions S93 and Y98 increased the yields of assembly of FMDV
O1/Campos empty capsids. The phenotype exhibited by this
mutated VP2 confirmed previously reported results indicating
that a 10-residue region spanning α-helix A (amino acids 88–98
for the O serotype) of VP2 protein is relevant for the infectivity
and stability of FMDV (Ellard et al., 1999; Porta et al., 2013;
Kotecha et al., 2015; Ganji et al., 2018). Furthermore, these studies
have shown that residues within this region are responsible
for non-covalent interactions between adjacent pentamers at
the icosahedral two-fold axis, where neighboring VP2–VP2
proteins interact. As shown in the O1/Campos VP2 model, these
residues are likely committed to local inter-pentameric subunit
associations (Figure 2).
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FIGURE 8 | Bone marrow dendritic cell (BMDC) activation induced by Ad5[P] or Ad5[PVP2]OP infection. BMDCs were infected with Ad5[P] or Ad5[PVP2]OP at
multiplicity of infection (MOI) of 50 and 250, as described in the section “Materials and Methods.” Then, the cells were stained with specific monoclonal antibodies
(mAbs) for phenotypic and activation markers and analyzed by flow cytometry. (A) Representative histograms depict the fluorescence intensities of CD80, CD86, and
major histocompatibility complex (MHC) class II molecules on MHCII+CD11c+ gated population. (B) Bars represent the geometric mean of fluorescence intensity
(MFI) ± SD. Isotype, cells were stained with control isotype mAbs; LPS-stimulated, cells were treated with 500 ng/ml lipopolysaccharide (LPS). *p < 0.05,
**p < 0.01, ***p < 0.001 compared to non-stimulated cells (ANOVA).
The serological data reinforce the initial hypothesis since
the amount of FMDV transgene expressed by Ad5[PVP2]OP
(and Ad5[P]OP) is sufficient to elicit a strong immune
response in mice, comparable to the oil-adjuvanted inactivated
O1/Campos FMDV vaccine. It is of note that the humoral
and protective responses against FMDV detected in our
murine model have a good established correlation with
cattle (Habiela et al., 2014; Bidart et al., 2020; Gnazzo
et al., 2020). We demonstrated that the Ad5[PVP2]OP vaccine
candidate elicited an enhanced antibody response as compared
to our first-generation vector, Ad5[P] (Figures 6A, 7B).
Notably, 94% of the animals inoculated with Ad5[PVP2]OP
were completely protected from a severe FMD virus challenge
(Figure 7A), which suggests that, at a similar dose of the
tried Ad5-vectored vaccines, Ad5[PVP2]OP provides additional
expression of the FMDV proteins and/or ability in antigen
presentation to immune cells sufficient to protect the vaccinated
animals. It is known that a higher antigenic mass of the
O1/Campos strain is required to achieve equivalent potency
in inactivated vaccines as compared to other serotype antigens
(Doel et al., 1994; Doel, 2003; Pena et al., 2008). It appears
that the efficacy of the Ad5-vectored O1/Campos vaccine
is also dependent on the amount of transgene expressed
in transduced cells. In this regard, significant differences in
transgene expression were detected in the dPLN populations
isolated from mice inoculated with Ad5[PVP2]OP or Ad5[P]
(Figure 5). While the levels of RNA do not necessarily
correlate with the protein expression levels determined in vitro
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(Figure 3), these differences in FMDV RNA levels could
explain the improved efficacy and the higher potency elicited
by the Ad5[PVP2]OP candidate in vivo as compared to
the Ad5[P] vector.
The levels of neutralizing antibodies were markedly higher in
mice inoculated with Ad5[PVP2]OP than in those inoculated with
Ad5[P] (Figure 7B). Although serum-neutralizing antibodies
have been considered the most relevant parameter that correlates
with protection against FMDV (Doel, 2003; Paton et al., 2005;
World Organisation for Animal Health, 2012), the contribution
of non-neutralizing antibodies in the protection against infection
and disease has also been described (McCullough et al.,
1992; Pay and Hingley, 1992; Dunn et al., 1998). In this
sense, higher levels of isotype IgG1 and IgG2a specific
antibodies were quantified in the groups inoculated with
the optimized vectors than in those mice inoculated with
Ad5[P] (Figures 6B,C). These increased IgG1 and IgG2a
specific antibodies may have played a relevant role in FMDV
opsonization and its subsequent clearance by phagocytic cells
of the immune system (McCullough et al., 1988). Further
studies to explore the contribution of other mechanisms
involved in the protection induced by Ad5[PVP2]OP in the
mouse model, as the induction of a detectable T cell
response, are needed.
Dendritic cells (DCs) play an important role in both
the initiation of innate immunity and the development of
adaptive immunity (Hochrein and O’Keeffe, 2008). Previous
reports have demonstrated that recombinant Ad5 induces the
maturation of dendritic cells by upregulating the expression
of major histocompatibility complex class I and II antigens,
co-stimulatory molecules (CD40, CD80, and CD86), and the
adhesion molecule CD54 (ICAM-1) (Morelli et al., 2000). The
preliminary shown in this work suggested that BMDCs infected
with Ad5[P] or Ad5[PVP2]OP upregulated the expression of
MHC class II and co-stimulatory molecules (CD80 and CD86)
to a similar extent (Figure 8). This data adds evidence to
previous reports that demonstrated that an unequal relationship
exists between the rate of transgene expression and the extent
of DC maturation (Morelli et al., 2000; Miller et al., 2003;
Philpott et al., 2004). FMDV structural and non-structural
proteins have been shown to antagonize the host innate
response in mammalian cells by preventing the translational
(Guzylack-Piriou et al., 2006) or transcriptional (de Los Santos
et al., 2006) regulation of host proteins. Although Ad5 vectors
expressing FMDV proteins seem to induce BMDCs to adopt an
activated phenotype, it remains unclear whether other biological
functions of these cells, which include antigen uptake, migration
to regional lymph nodes, and antigen-specific T-lymphocyte
activation, are affected.
When the optimized vectors were compared in mouse
challenge experiments, a remarkable finding was the ability of
the Ad5[PVP2]OP candidate to confer higher protection than
Ad5[P]OP (94% and 60%, respectively). Evaluation of specific
parameters of the humoral immune response such as total
specific antibody titers, isotype balance, and specific antibody
avidity indicated no significant difference in these attributes
(Figure 6). In this scenario, differences in other responses
such as innate and cellular immunity cannot be discarded.
For example, an increased antibody-dependent phagocytosis
(Lannes et al., 2012; Quattrocchi et al., 2011) and T CD8-
mediated cytotoxicity (Guzman et al., 2010; Patch et al.,
2013) may exert a synergistic effect, explaining the higher
protection afforded by Ad5[PVP2]OP. Furthermore, our results
may indicate that elements in addition to transgene expression
levels are likely to have the potential to significantly influence
the enhanced resistance to challenge in Ad5[PVP2]OP-vaccinated
animals. It is then tempting to suggest that the superior
ability of Ad5[PVP2]OP in the assembly of FMDV VLPs
shown in vitro may have accounted for its enhanced efficacy
in vivo.
One of the foremost factors reported to influence the
potency of vaccine preparations is the structural integrity of
the whole (146S) FMD viral particles, mainly due to the
capacity of this antigen to elicit antibodies against exposed
epitopes that can drive to viral clearance in the case of a
natural infection (Cartwright et al., 1982; Doel and Chong,
1982; Rao et al., 1994). In particular, neutralizing antibody
production is associated mainly with 146S particles (Bahnemann,
1975; Pay and Hingley, 1992), whereas disrupted viral particles
(12S pentamers) are less immunogenic and elicit a diminished
neutralizing response (Doel and Chong, 1982; Rao et al.,
1994). It has recently been demonstrated that FMDV-specific
production of IFN-γ is strongly affected by the integrity of
the viral capsids (Bucafusco et al., 2015). Additionally, FMDV-
specific IFN-γ production in vaccinated cattle has been associated
with the activation of antigen-specific CD4+ T cells (Oh
et al., 2012), which are responsible for supporting antibody-
neutralizing responses (Carr et al., 2013). In this regard,
a comparative analysis of the antigenic reactivity with a
panel of 13 mAbs specific for FMDV serotype O (Seki
et al., 2009) revealed that the FMDV subunits launched by
Ad5[PVP2]OP exhibit an improved reactivity with neutralizing
and non-neutralizing mAbs as compared to those antigens
generated by the assembly deficient Ad5[P]OP (Supplementary
Figure S2). Moreover, we demonstrated that the Ad5[PVP2]OP
vaccine candidate elicited moderate but significantly higher
titers of nAb than did Ad5[P]OP (Figure 7B). Therefore,
it is tempting to speculate that FMDV subunits generated
by the Ad5[PVP2]OP vaccine candidate form an oligomeric
protein scaffold capable of presenting immunogenic epitopes
and proteins in a more efficient manner, similar to the
native FMD virion.
Traditional inactivated FMDV vaccines have played and still
play a preponderant role in preventing and controlling the
disease worldwide (Caridi et al., 2017; Khalifa et al., 2017).
However, the drawbacks associated with its production, the
duration of immunity, the necessity of a strict cold chain to
preserve particle stability, among others, have led to continuous
attempts to develop a large variety of alternative FMD vaccines.
In this respect, we have generated the optimized Ad5[PVP2]OP
candidate which launches the expression of high levels of FMDV
O1/Campos subunits that partially self-associate into VLPs.
The results herein demonstrated the remarkable antigenicity
and efficacy of this platform in a very well-supported murine
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model. Notwithstanding, the potency of the Ad5[PVP2]OP vaccine
candidate should be further studied in target species, such as pigs
or cattle, whenever possible.
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Supplementary Figure 2 | Antigenic reactivity of FMDV subunits launched by
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Ad5[PVP2]OP were analyzed by using specific mAbs for O1/Campos FMDV by
ELISA. The reactivities of FMDV subunits against several mAbs are shown as the
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